PD‐1 checkpoint blockade led to tumour regression in ∼20% of patients with advanced HCC,27 and clinical trials on cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA‐4) blockade showed a partial response in ∼26% of HCC cases.28 The gene discussed is CTLA4; the disease is neoplasm.